Ruxolitinib synergizes with regulatory T cells to improve inflammation but has no added benefits in decreasing albuminuria in SLE

BackgroundUmbilical cord blood (UCB)-derived CD4+CD25+CD127low regulatory T cells (Tregs) can decrease albuminuria and anti-dsDNA IgG in systemic lupus erythematosus (SLE). Ruxolitinib, a JAK/STAT inhibitor, has been shown to improve cutaneous manifestations of SLE. We hypothesize that the addition...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Mi-Ae Lyu, Ximing Tang, Maria Gabriela Raso, Meixian Huang, Ke Zeng, Tara Sadeghi, Christopher R. Flowers, Simrit Parmar
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2025-02-01
Serie:	Frontiers in Immunology
Soggetti:	adoptive cell therapy regulatory T cells (Tregs) allogeneic umbilical cord blood (UCB) ruxolitinib JAK/STAT pathway
Accesso online:	https://www.frontiersin.org/articles/10.3389/fimmu.2025.1449693/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!